GT
SIOX

Glenmede Trust’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Glenmede Trust’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-175
Closed -$9K – 2837
2017
Q3 		$9K Buy
+175
New +$29.5K ﹤0.01% 2217
2017
Q1 		– Sell
-175
Closed -$17K – 2775
2016
Q4 		$17K Hold
175
– – ﹤0.01% 1952
2016
Q3 		$19K Hold
175
– – ﹤0.01% 1946
2016
Q2 		$17K Hold
175
– – ﹤0.01% 1949
2016
Q1 		$16K Hold
175
– – ﹤0.01% 1888
2015
Q4 		$25K Hold
175
– – ﹤0.01% 1788
2015
Q3 		$18K Buy
+175
New +$20.5K ﹤0.01% 1934

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Glenmede Trust's SIOX Position: Q4 2017 in Review

Glenmede Trust sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 175 shares — an estimated $9K sold.

Glenmede Trust first reported a position in SIOX in Q3 2015 and held it in 7 quarters. The position peaked at $25K in Q4 2015. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Glenmede Trust reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Glenmede Trust sold 175 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $9K.
  • Glenmede Trust first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 7 quarters.
  • Glenmede Trust's Sio Gene Therapies Inc. Common Stock position peaked at $25K in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Glenmede Trust's 13F filing for Q4 2017, filed 15 Feb 2018.